Is Ocugen About to Beat Moderna in This One Market?
This spring, the U.S. Food and Drug Administration (FDA) dashed Ocugen's (NASDAQ: OCGN) dreams of quickly commercializing its coronavirus vaccine candidate. The regulatory agency recommended Ocugen pursue the lengthy traditional route of an approval request instead of an Emergency Use Authorization (EUA) request. And that's what Ocugen is doing.
But Ocugen recently announced an additional plan. And if the plan is successful, the company could beat market-leader Moderna (NASDAQ: MRNA) in one specific area. Ocugen applied for the authorization of its vaccine candidate Covaxin in kids ages two through 18.
The FDA hasn't yet authorized Moderna's vaccine for that population. So what are the chances Ocugen will beat Moderna in this area?
Source Fool.com
